Comment on: Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low-risk clinical trials

Affiliations

¹ Department of Pediatrics, Children's of Alabama, University of Alabama at Birmingham, Birmingham, Alabama, USA.
² Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Comment

Jamie M Aye et al. Pediatr Blood Cancer. 2022 Jul.

. 2022 Jul;69(7):e29554.

doi: 10.1002/pbc.29554. Epub 2021 Dec 28.

¹ Department of Pediatrics, Children's of Alabama, University of Alabama at Birmingham, Birmingham, Alabama, USA.
² Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

No abstract available

Comment on

Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.
Aye JM, Xue W, Palmer JD, Walterhouse DO, Arnold MA, Heaton TE, Venkatramani R. Aye JM, et al. Pediatr Blood Cancer. 2021 Apr;68(4):e28914. doi: 10.1002/pbc.28914. Epub 2021 Jan 26. Pediatr Blood Cancer. 2021. PMID: 33501771 Free PMC article. Clinical Trial.
Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low-risk clinical trials.
Spunt SL. Spunt SL. Pediatr Blood Cancer. 2022 Jan;69(1):e29399. doi: 10.1002/pbc.29399. Epub 2021 Oct 6. Pediatr Blood Cancer. 2022. PMID: 34613653 No abstract available.